Company Filing History:
1 out of 37 
1 out of 1 Years Active: 1993
Title: Innovations of Tokio Kaizu in Monoclonal Antibody Research
Introduction
Tokio Kaizu is a notable inventor based in Seattle, Washington, recognized for his contributions to the field of biotechnology. He holds a patent for a groundbreaking monoclonal antibody that has significant implications for contraception and infertility treatment in human females. His work exemplifies the intersection of scientific research and practical applications in medicine.
Latest Patents
Kaizu's most recent patent is for the monoclonal antibody NUH2, which is capable of inactivating the motility of human sperm. This invention is produced by a hybridoma with the ATCC deposit number HB 9762. The patent also describes an isolated antigen that specifically binds to anti-human sperm antibodies, including NUH2, and comprises at least an epitope with a sialyl I structure. The methods outlined in the patent detail the use of this monoclonal antibody and antigen for contraception and treating infertility in women.
Career Highlights
Throughout his career, Tokio Kaizu has worked with esteemed organizations such as the Biomembrane Institute and Hyogo Medical College. His research has contributed to advancements in reproductive health and has the potential to impact many lives positively.
Collaborations
Kaizu has collaborated with notable colleagues, including Edward D. Nudelman and Ulla Mandel-Clausen. Their combined expertise has furthered the development of innovative solutions in the field of reproductive medicine.
Conclusion
Tokio Kaizu's work in developing the monoclonal antibody NUH2 represents a significant advancement in biotechnology, particularly in the areas of contraception and infertility treatment. His contributions continue to influence the medical field and offer hope for many individuals seeking solutions to reproductive challenges.